Zhitong Finance App News, Lukang Pharmaceutical (600789.SH) issued an announcement. The company received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for lenvatinib mesylate issued by the State Drug Administration, and the drug approved the marketing application. This drug is a tyrosine kinase receptor (RTK) inhibitor for patients with unresectable hepatocellular carcinoma who have not previously received systemic treatment.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.